Mechanisms and use of calcium-sensitizing agents in the failing heart

Circulation

Volumn 113, Issue 2, 2006, Pages 305-315

  Kass, David A ^a   Solaro, R John ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Calcium; Cardiomyopathy; Heart failure; Myocardial contraction; Pharmacology

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 4 [3 (4 BENZHYDRYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY] 1H INDOLE 2 CARBONITRILE; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ALLOPURINOL; ANTIOXIDANT; CALCIUM ION; CALCIUM SENSITIZER; CK 1213296; CK 1827452; DIURETIC AGENT; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; LY 379196; MYOSIN ACTIVATOR; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; OXIPURINOL; PHOSPHODIESTERASE III INHIBITOR; PIMOBENDAN; PLACEBO; PROTEIN KINASE C INHIBITOR; TROPOMYOSIN; TROPONIN C; TROPONIN I; UNCLASSIFIED DRUG; VASODILATOR AGENT; XANTHINE OXIDASE INHIBITOR; CALCIUM; CARDIOTONIC AGENT;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; CALCIUM CELL LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXCITATION CONTRACTION COUPLING; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MORTALITY; MYOFILAMENT; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TACHYCARDIA; TREATMENT OUTCOME; VOMITING; DRUG EFFECT; METABOLISM; MICROFILAMENT;

CALCIUM; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; MICROFILAMENTS;

EID: 33644997173     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.542407     Document Type: Review

References (78)

1. Blinks JR, Endoh M. Modification of myofibrillar responsiveness to Ca++ as an inotropic mechanism. Circulation. 1986;73(suppl III):III-85-III-98.
2. Bers DM. Excitation Contraction Coupling and Cardiac Contractile Force. Dordrecht, Netherlands: Kluwer Academic Publishers; 2001.
3. Kobayashi T, Solaro RJ. Calcium, thin filaments, and the integrative biology of cardiac contractility. Annu Rev Physiol. 2005;67:39-67.
4. Solaro RJ. Modulation of Cardiac Myofilament Activity by Protein Phosphorylation. New York, NY: Oxford University Press; 2002.
5. 2+ sensitivity in intact versus skinned rat ventricular muscle. Circ Res. 1994;74:408-415.
6. Soergel DG, Georgakopoulos D, Stull LB, Kass DA, Murphy AM. Augmented systolic response to the calcium sensitizer EMD-57033 in a transgenic model with troponin I truncation. Am J Physiol Heart Circ Physiol. 2004;286:H1785-H1792.
7. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77:107-113.
8. Granzier HL, Labeit S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res. 2004;94:284-295.
9. Spyracopoulos L, Li MX, Sia SK, Gagne SM, Chandra M, Solaro RJ, Sykes BD. Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry. 1997;36:12138-12146.
10. Dong WJ, Xing J, Villain M, Hellinger M, Robinson JM, Chandra M, Solaro RJ, Umeda PK, Cheung HC. Conformation of the regulatory domain of cardiac muscle troponin C in its complex with cardiac troponin I. J Biol Chem. 1999;274:31382-31390.
11. Gordon AM, Rivera AJ, Wang CK, Regnier M. Cooperative activation of skeletal and cardiac muscle. Adv Exp Med Biol. 2003;538:371-378.
12. Solaro RJ, Bousquet P, Johnson JD. Stimulation of cardiac myofilament force, ATPase activity and troponin C Ca++ binding by bepridil. J Pharmacol Exp Ther. 1986;238:502-507.
13. Li Y, Love ML, Putkey JA, Cohen C. Bepridil opens the regulatory N-terminal lobe of cardiac troponin C. Proc Natl Acad Sci U S A. 2000; 97:5140-5145.
14. Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR. Interaction of bepridil with the cardiac troponin C/troponin I complex. FEBS Lett. 2001;506:51-54.
15. Sumandea MP, Burkart EM, Kobayashi T, de Tombe PP, Solaro RJ. Molecular and integrated biology of thin filament protein phosphorylation in heart muscle. Ann N Y Acad Sci. 2004;1015:39-52.
16. Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, Beier N, Lakatta EG. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res. 1993;73:981-990.
17. Pan BS, Johnson RG Jr. Interaction of cardiotonic thiadiazinone derivatives with cardiac troponin C. J Biol Chem. 1996;271:817-823.
18. 2+ sensitizing drug EMD 57033. J Biol Chem. 2001;276:25456-25466.
19. Rosevear PR, Finley N. Molecular mechanism of levosimendan action: an update. J Mol Cell Cardiol. 2003;35:1011-1015.
20. Bodi A, Szilagyi S, Edes I, Papp Z. The cardiotonic effects of levosimendan in guinea pig hearts are modulated by beta-adrenergic stimulation. Gen Physiol Biophys. 2003;22:313-327.
21. Urboniene D, Dias FA, Pena JR, Walker LA, Solaro RJ, Wolska BM. Expression of slow skeletal troponin I in adult mouse heart helps to maintain the left ventricular systolic function during respiratory hypercapnia. Circ Res. 2005;97:70-77.
22. Layland J, Cave AC, Warren C, Grieve DJ, Sparks E, Kentish JC, Solaro RJ, Shah AM. Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I. FASEB J. 2005;19:1137-1139.
23. 2+ protects murine myocardium against ischemia/reperfusion dysfunction. Am J Physiol Heart Circ Physiol. 2005;289:H2183-H2192.
24. 2+-regulated actomyosin S1 ATPase. J Biol Chem. 2002;277: 34662-34665.
25. Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac myosin binding protein C: its role in physiology and disease. Circ Res. 2004;94:1279-1289.
26. Palmer BM, Georgakopoulos D, Janssen PM, Wang Y, Alpert NR, Belardi DF, Harris SP, Moss RL, Burgon PG, Seidman CE, Seidman JG, Maughan DW, Kass DA. Role of cardiac myosin binding protein C in sustaining left ventricular systolic stiffening. Circ Res. 2004;94: 1249-1255.
27. Takeishi Y, Chu G, Kirkpatrick DM, Li Z, Wakasaki H, Kranias EG, King GL, Walsh RA. In vivo phosphorylation of cardiac troponin I by protein kinase Cbeta2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts. J Clin Invest. 1998;102: 72-78.
28. Senzaki H, Isoda T, Paolocci N, Ekelund U, Hare JM, Kass DA. Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. Circulation. 2000; 101:1040-1048.
29. Hajjar RJ, Schmidt U, Helm P, Gwathmey JK. Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther. 1997;280:247-254.
30. Tobias AH, Slinker BK, Kirkpatrick RD, Campbell KB. Functional effects of EMD-57033 in isovolumically beating isolated rabbit hearts. Am J Physiol. 1996;271:H51-H58.
31. Slinker BK, Green HW III, Wu Y, Kirkpatrick RD, Campbell KB. Relaxation effect of CGP-48506, EMD-57033, and dobutamine in ejecting and isovolumically beating rabbit hearts. Am J Physiol. 1997; 273:H2708-H2720.
32. Bell SP, Nyland L, Tischler MD, McNabb M, Granzier H, LeWinter MM. Alterations in the determinants of diastolic suction during pacing tachycardia. Circ Res. 2000;87:235-240.
33. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC, Cheng CP. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol. 2005;288:H914-H922.
34. Suga H. Ventricular energetics. Physiol Rev. 1990;70:247-277.
35. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA, Hare JM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002;90:297-304.
36. Cleland JG, Nikitin N, McGowan J. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Rev Cardiovasc Ther. 2004;2:9-19.
37. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem. 2004;266:87-107.
38. Frishman WH. Advances in positive inotropic therapy: levosimendan. Crit Care Med. 2003;31:2408-2409.
39. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy. 2004;24:1366-1384.
40. Papp Z, Csapo K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005;23:71-98.
41. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859-1866.
42. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol. 1995;27:2155-2165.
43. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147.
44. Takahashi R, Endoh M. Dual regulation of myofilament Ca(2+) sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br J Pharmacol. 2005;145:1143-1152.
45. Ajiro Y, Hagiwara N, Katsube Y, Sperelakis N, Kasanuki H. Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol. 2002;435:27-33.
46. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol. 2001;428:311-314.
47. + channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-259.
48. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504-1509.
49. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther. 1996;279:120-127.
50. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol. 2004;43:555-561.
51. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522-531.
52. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81-86.
53. Antila S, Kivikko M, Lehtonen L, Eha J, Heikkila A, Pohjanjousi P, Pentikainen PJ. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol. 2004;57:412-415.
54. Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail. 2003;5:101-108.
55. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432.
56. Zairis M. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: CASINO study. J Am Coll Cardiol. 2004;43:206A. Abstract.
57. Garratt C, Packer M, Colucci W, Fisher L, Massie B, Teerlink J, Young J. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. Crit Care. 2004;8(suppl 1):89. Abstract.
58. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Presented at the 2005 American Heart Association Scientific Sessions, Dallas, Tex, November 14, 2005.
59. The SURVIVE-W trial: comparison of dobutamine and levosimendan on survival in acutely decompensated heart failure. Presented at the 2005 American Heart Association Scientific Sessions, Dallas, Tex, November 16, 2005.
60. Hata K, Goto Y, Futaki S, Ohgoshi Y, Yaku H, Kawaguchi O, Takasago T, Saeki A, Taylor TW, Nishioka T, Suga H. Mechanoenergetic effects of pimobendan in canine left ventricles. Circulation. 1992;82:1291-1301.
61. Remme WJ, Kruijssen DA, van Hoogenhuyze DC, Krauss XH, Bartels GL, Storm CJ, de Leeuw PW. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. J Cardiovasc Pharmacol. 1994;24:730-739.
62. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, Dumont JM, Seed P. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223-231.
63. Sata M, Sugiura S, Yamashita H, Aoyagi T, Momomura S, Serizawa T. Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin. Eur J Pharmacol. 1995;290:55-59.
64. Murphy AM, Kogler H, Georgakopoulos D, McDonough JL, Kass DA, Van Eyk JE, Marban E. Transgenic mouse model of stunned myocardium. Science. 2000;287:488-491.
65. 2+ sensitivity of reconstituted thin filament: a study using a novel in vitro motility assay technique. Circ Res. 1995;76:626-633.
66. Korvald C, Nordhaug DO, Steensrud T, Aghajani E, Myrmel T. Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca(2+)-sensitizer" MCI-154 in intact pigs. Scand Cardiovasc J. 2002; 36:172-179.
67. 2+ sensitizer, decreases the oxygen cost of contractility in isolated canine hearts. Am J Physiol. 1997;273:H1688-H1695.
68. 2+ sensitizer, MCI-154, reduces myocardial oxygen consumption for non-mechanical work in diseased human hearts. Circulation. 1994;90(suppl II):I-217. Abstract.
69. Kawabata Y, Endoh M. Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993;72:597-606.
70. Okafor C, Liao R, Perreault-Micale C, Li X, Ito T, Stepanek A, Doye A, de Tombe P, Gwathmey JK. Mg-ATPase and Ca+ activated myosin ATPase activity in ventricular myofibrils from non-failing and diseased human hearts: effects of calcium sensitizing agents MCI-154, DPI 201-106, and caffeine. Mol Cell Biochem. 2003;245:77-89.
71. Flesch M, Erdmann E. Na+ channel activators as positive inotropic agents for the treatment of chronic heart failure. Cardiovasc Drugs Ther. 2001;15:379-386.
72. Malik F, Shen YT, Katori T, Sueoka SH, Anderson R, Cox D, Garard M, Hartmen J, Kim SJ, Kraynack E, Kuklov A, Lee KH, Lu PP, Muci A, Niu C, Rodrigez H, Suehiro I, Sylverster S, Tochimoto T, Elias KA, Morgan BP, Sakowicz R, Kass DA, Vatner SF, Morgans DJ. Direct activation of cardiac myosin, a novel mechanism for improving cardiac function. Circ Res. 2005;97:e34. Abstract.
73. Malik F, Elias KA, Finer JT, Morgan BP, Sakowicz R, Anderson R, Baliga R, Conn L, Cox D, Garard M, Hartman J, Irvine J, Kawas R, Kraynack E, Kuklov A, Lee KH, Lu P, Muci D, Pierce DW, Rodriguez H, Suehiro I, Sueoka SH, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. J Card Fail. 2005;11(suppl):S95. Abstract.
74. Canton M, Neverova I, Menabo R, Van Eyk J, Di Lisa F. Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. Am J Physiol Heart Circ Physiol. 2004;286:H870-H877.
75. 2+-sensitizing property of xanthine oxidase inhibitors. Circ Res. 1998;83:423-430.
76. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, Kass DA, Marban E, Hare JM. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999;85:437-445.
77. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.
78. Freudenberger RS, Schwarz RP Jr, Brown J, Moore A, Mann D, Givertz MM, Colucci WS, Hare JM. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class. Expert Opin Investig Drugs. 2004;13:1509-1516.